Comparative Pharmacology
Head-to-head clinical analysis: LYSODREN versus XOSPATA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSODREN versus XOSPATA.
LYSODREN vs XOSPATA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adrenocorticolytic agent; causes adrenal cortical necrosis and suppresses adrenal steroidogenesis, especially glucocorticoids and mineralocorticoids.
Gilteritinib is a tyrosine kinase inhibitor that inhibits FLT3 (FMS-like tyrosine kinase 3) receptor signaling, including FLT3-ITD and FLT3-TKD mutations, leading to apoptosis in leukemic cells.
Oral, initial dose 2-6 g/day divided in 3-4 doses, increase gradually to 8-10 g/day. Maximum dose 18 g/day.
120 mg orally once daily.
None Documented
None Documented
18-159 days; clinical context: during chronic therapy, steady-state may not be reached for 3-6 months.
Terminal half-life 9.1 hours (range 4.4–16.1 hours); supports once-daily dosing.
Primarily renal excretion of metabolites; about 10% as unchanged drug. Biliary/fecal excretion accounts for <5%.
Fecal (64%) and renal (16%) as metabolites; <1% unchanged in urine.
Category C
Category C
Antineoplastic
Antineoplastic